Cytoreductive nephrectomy in metastatic renal cancer.
Recent randomized prospective trials have suggested that cytoreductive nephrectomy confers a survival advantage in patients with metastatic renal cancer who receive immunotherapy with interferon-alfa-2b. It appears that the patients most benefiting from this approach are those with good performance status, lung-only metastases, and adequate cardiac and pulmonary reserve. Nonrandomized trials have further suggested that this survival advantage may be extended in patients who receive more aggressive interleukin-2-based immunotherapy.
Flanigan
Robert C
RC
Department of Urology, Loyola University Stritch School of Medicine, Building 54, Room 237A, 2160 S. First Avenue, Maywood, IL 60153, USA. rflanig@lumc.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000601:surgery* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D009392:Nephrectomy / Q000379:methods; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins